流式细胞术检测 中国就医指南

Flow cytometry is not a disease but a highly sensitive, multiparametric laboratory technique used extensively in hematology for the identification, quantification, and functional analysis of individual cells—particularly blood and bone marrow cells—based on their physical and chemical characteristics. It plays a pivotal role in diagnosing, classifying, monitoring, and prognosticating hematologic malignancies such as acute leukemias (AML, ALL), lymphomas, myelodysplastic syndromes (MDS), multiple myeloma, and chronic lymphoproliferative disorders. The method relies on suspending cells in a fluid stream and passing them single-file through one or more laser beams; fluorescently labeled monoclonal antibodies bind to specific cell surface or intracellular antigens (e.g., CD markers), and emitted light signals are detected to generate immunophenotypic profiles. Pathogenically, flow cytometry does not cause disease but detects aberrant antigen expression patterns—such as asynchronous antigen co-expression, abnormal intensity, or lineage infidelity—that reflect underlying clonal dysregulation, genetic instability, or malignant transformation in hematopoietic stem/progenitor cells. Epidemiologically, its clinical application spans all age groups but is most critical in pediatric and adult acute leukemia diagnosis (incidence: ~5–10 cases per 100,000 annually in China), where it enables rapid, objective classification aligned with WHO and ELN guidelines. Risk factors for conditions requiring flow cytometry evaluation include prior chemotherapy/radiation exposure, inherited bone marrow failure syndromes (e.g., Fanconi anemia), autoimmune cytopenias, unexplained cytopenias or lymphocytosis, and family history of hematologic neoplasms. While flow cytometry itself is non-invasive and carries no direct morbidity, delays or inaccuracies in its interpretation can significantly impact clinical decision-making—leading to misdiagnosis, inappropriate therapy, or missed minimal residual disease (MRD) detection. This directly affects quality of life: timely, precise immunophenotyping informs risk-adapted treatment, reduces unnecessary chemotherapy toxicity, supports early MRD-guided intervention, and improves survival outcomes—especially in high-risk subtypes. Patients benefit from shorter diagnostic odysseys, reduced need for repeat biopsies, and more personalized therapeutic pathways. As a cornerstone of modern hematopathology, flow cytometry also underpins clinical trials evaluating novel immunotherapies (e.g., CAR-T, bispecific antibodies), where precise target antigen characterization is essential. Its utility extends beyond oncology—to immune deficiency assessment (e.g., HIV CD4 counts), paroxysmal nocturnal hemoglobinuria (PNH) clone detection, and post-transplant immune reconstitution monitoring. Continuous advancements—including spectral flow cytometry, mass cytometry (CyTOF), and automated data analysis—enhance resolution, reproducibility, and accessibility across tiered healthcare settings in China.

# 流式细胞术检测（血液科）治疗方案与费用明细指南

一、非手术/保守检测方案

适用于初筛、疗效监测、微小残留病（MRD）评估及白血病/淋巴瘤分型患者。

• •基础免疫分型检测（CD3/CD19/CD34/CD117等8色）：¥800–¥1,200（含标本处理、抗体染色、上机分析）
• •MRD深度检测（≥10色，敏感度10⁻⁴）：¥2,200–¥3,500（含双管重复验证、报告解读）
• •多参数功能检测（如胞内因子、凋亡、P-gp耐药检测）：¥1,800–¥2,800/项

二、手术/介入关联方案

流式本身为体外检测技术，无手术或微创操作；但常作为骨髓穿刺/活检、CAR-T治疗前后的核心评估手段。

• •骨髓穿刺术（含流式送检）：¥1,500–¥2,000（含穿刺费¥300 + 流式基础检测¥1,200）
• •CAR-T治疗前MRD动态监测（3次/疗程）：¥6,600–¥10,500（含术前基线+回输后d14/d30检测）

三、特殊复杂场景方案

• •复发/难治性AML/MDS患者（需≥20色高维分析+生物信息学建模）：¥4,500–¥6,800/次
• •移植后嵌合率+MRD联合检测（STR+流式双平台）：¥3,200–¥4,800

四、方案快速选择指南

• •预算有限初筛者 → 选基础免疫分型（¥800）
• •ALL/AML化疗患者 → 必选MRD检测（¥2,200起），每疗程至少2次
• •CAR-T或移植候选者 → 选MRD+嵌合率联合方案（¥4,500起）
• •疑难复发病例 → 启动高维流式+生信分析（¥5,000+）